Chuah CH, Chow TS, Hor CP, et al. - An open-label, randomized clinical trial investigating the effect of favipiravir in preventing disease progression from non-hypoxia to hypoxia among high risk COVID-19 patients.

• A total of 500 symptomatic, RT-PCR confirmed COVID-19 patients (aged ≥ 50 years), who had ≥ one comorbidity, and were hospitalized within the first 7 days of illness, were randomized to receive favipiravir plus standard care or standard care alone.

• Per outcomes, early treatment with oral favipiravir did not correlate with prevention of the disease progression from non-hypoxia to hypoxia among COVID-19 patients at high risk of disease progression .